Survey for CLL patients having taken Venetocla... - CLL Support

CLL Support

23,335 members40,040 posts

Survey for CLL patients having taken Venetoclax or Acalabrutinib

CLL_Canada_Group profile image

CLL/SLL Patient Survey

If you have CLL or SLL and have been treated with the following therapies, you can help by completing our survey:

Venetoclax (Venclexta) + obinutuzumab (Gazyva) for first-line treatment of CLL/SLL

Acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) for first-line treatment of CLL/SLL

Acalabrutinib (Calquence) monotherapy for treatment of relapsed/refractory CLL/SLL

Lymphoma Canada and CLL Patient Advocacy Group (CLLPAG) are preparing submissions for the pan­Canadian Oncology Drug Review (pCODR) so that CLL/SLL patients in Canada can gain access to these therapies.

You can help by completing our survey, which will provide us with the patient input required for the submission. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs. You do not need to live in Canada to complete this survey.

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THESE NEW TREATMENTS IN CANADA.

The survey will be open until midnight Pacific Time on Friday, February 7th, 2020 and should only take 10 minutes of your time.

You may access the survey by clicking the link below.

surveymonkey.com/r/CLLCAN2020

Thank you!

Rebecca Drotos

Written by
CLL_Canada_Group profile image
CLL_Canada_Group
To view profiles and participate in discussions please or .
Read more about...

The ability to reply to this post has been turned off.

15 Replies
sllincolorado profile image
sllincolorado

Thank you for conducting this survey.

I was on Ibrutinib for one month and then switched to acalabrutinib. Do you want me to select that acalabrutinib was first line or for refractory or none of the above. The reason I switched was side effects. I know there are many other patients in similar situations. They switched not because of refractory but because of inability to handle side effects.

CLL_Canada_Group profile image
CLL_Canada_Group in reply tosllincolorado

This counts as front line for the purpose of the survey - thanks!

CLL_Canada_Group profile image
CLL_Canada_Group in reply tosllincolorado

Hi sllincolorado - I was wrong. Our survey must be for the purposes of the Canadian submission which was very specific, and therefore excludes any indication OTHER than those specifically indicated in the survey. Sorry for the confusion! - Rebecca

aquafinn profile image
aquafinn

Rebecca,

I am currently in EA9161 clinical trial first line. I was randomized for the O+I+V. Should I do the survey?

CLL_Canada_Group profile image
CLL_Canada_Group in reply toaquafinn

Yes, i believe anyone using venetoclax can respond.

CLL_Canada_Group profile image
CLL_Canada_Group in reply toaquafinn

Hi aquafinn - clarification. The indication we need to survey is specific, so go ahead and take the survey and if the questions do not allow you to proceed, just answer them correctly. Apologies if i was in error before. - Rebecca

Jackpot profile image
Jackpot

Hi. I am in a clinical trial and take acalabrutinib and venetoclax as a front tine treatment. Should I do the survey?

CLL_Canada_Group profile image
CLL_Canada_Group in reply toJackpot

I believe so, yes. There are places where you can explain your circumstance using text input. We will certainly re-examine our click and skip questions for future surveys ... Let us know if the logic does not allow you to answer the way you wish. We can revisit some of the survey questions and click logic .. Thank you!!

Jackpot profile image
Jackpot in reply toCLL_Canada_Group

Thank you. I completed the survey stating that I also take venetoclax as part of a clinical trial.

bulldozer4264 profile image
bulldozer4264

Looks like your survey has missed all those people who switched from Ibrutinib to Acalabrutinib because of adverse or undesirable side effects. Too bad, because there are many who are in that situation.

CLL_Canada_Group profile image
CLL_Canada_Group in reply tobulldozer4264

Hi - I have changed my response here. The survey supports a drug submission in Canada and as such has to be for the exact indication as submitted - hence the questions as they are. I encourage all to take the survey and answer the questions exactly, the question logic should help figure out if the survey fits your situation. Sorry for any confusion ... --Rebecca

Maloncll profile image
Maloncll in reply tobulldozer4264

Agreed

HAIRBEAR_UK profile image
HAIRBEAR_UKFounder Admin

Hi everyone, this survey @ surveymonkey.com/r/CLLCAN2020

can also be completed by any UK and patients in other countries outside Canada who are being treated or have been treated as below.

Venetoclax + obinutuzumab 1st line, or

Acalabrutinib with or without obinutuzumab 1st line, or

Acalabrutinib monotherapy after relapse

This survey will help support access submissions in countries outside of Canada too.

WE NEED YOUR UK input

Please can you help if you have received these experimental therapies in a clinical trial

Many thanks

Nick

Eucalyptus22 profile image
Eucalyptus22

Happy to complete survey. Have been on Acalabrutinib for 6 months as front line treatment and it has been very successful.

rvles profile image
rvles

Please be advised that this survey has ended and that responses are no longer accepted. Thank you to all those who participated.

The ability to reply to this post has been turned off.

Not what you're looking for?

You may also like...

Please share experience of venetoclax plus obinutuzimab or acalabrutinib mono treatment in an important survey

Reminder - please complete the survey if you are any of the above treatments. At the moment we...
Jm954 profile image
Administrator

ATTENTION CLL + SLL PATIENTS AND CAREGIVERS

Lymphoma Canada and the CLL Patient Advocacy Group (CLLPAG) is preparing a submission for the...
LCAdmin profile image

CLL patients with idelalisib (Zydelig) experience

Lymphoma Canada is conducting a survey of CLL patients to appeal to Canadian governments to provide...
LCAdmin profile image

Results on triple combination (A+V+O) for high risk patients -with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-cll

The Bottom Line: In this ongoing trial, the triple combination therapy using acalabrutinib,...
spi3 profile image

Research survey on CLL/SLL

Hi We are doing some research in follow up to our abstract from ASH 2016 and would appreciate your...
bkoffman profile image
CLL CURE Hero

Moderation team

See all
CLLerinOz profile image
CLLerinOzAdministrator
AussieNeil profile image
AussieNeilAdministrator
Newdawn profile image
NewdawnAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.